Analysts at Healthcare Intelligence Markets Has Anticipated the Global Parkinson’s Diseases Treatment Market to Grow at a CAGR of Around +5% During the Forecast Period 2018 to 2026
Parkinson’s disease primarily exhibits muscle stiffness, causes tremors, improper motor movements, and gait and balance problems. As the disease progresses, the patient starts to suffer from loss of memory, imbalances, and anxiety. Although there is no cure for this disease, its associated complications leads to death because a significant amount of the substantia nigra neurons have already been lost or impaired. There are no fixed causes of this disease, however it is commonly traced back to the history of genetic implications. Co-coordinating with a neurologist abiding by the recommended therapies are the most essential steps that can in successfully treat symptoms by using dopaminergic medications.
For Sample Copy of this report: https://www.healthcareintelligencemarkets.com/request_sample.php?id=29017
The Global Parkinson’s Diseases Market is driven by growing geriatric population among both developed countries and emerging countries like India and China. Changing lifestyle of people is propelling the incidences of this disease and which is ultimately driving demand for its associated therapeutic solutions.
The Global Parkinson’s Diseases has been segmented by Drug Class into Carbidopa/Levodopa, Dopamine Receptor Agonists, and MAO-Inhibitors. The report grants extensive insights into the real nature of the market by undertaking the study done on the factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges. Asian region, amongst the global marketspace, held the highest market share and is anticipated to be the fastest growing in terms of future prospects.
The competitive analysis done describes that the market is consolidated by the presence of some key players. Some of the prominent competitors include Novartis AG, F. AbbVie Inc., Teva Pharmaceutical Industries Ltd., Hoffmann-La Roche AG, and UCB Inc. According to a latest news, Teva Pharmaceutical Industries Ltd have doubled their market presence by launching their neurological franchise through significant success with COPAXONE (glatiramer acetate injection) for the reduction of relapses among Parkinson’s patients.
Avail Discount on this report: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=29017
Parkinson’s Disease Treatment Market – by Drug Class
• Dopamine Receptor Agonists
Parkinson’s Disease Treatment Market – Distribution Channel
• Hospital, Online
• Retail Pharmacies
Parkinson’s Disease Treatment Market – by Patient Care Setting
Parkinson’s Disease Treatment Market – by Region
• North America
• Rest of North America
• The UK
• Rest of Europe
• Asia Pacific
• Southeast Asia
• Rest of Asia Pacific
• Middle East and Africa
• GCC Countries
• Southern Africa
• Rest of Middle East and Africa
• Latin America
• Rest of Latin America
The market report provides both, qualitative and quantitative research of the market, as well as provides worthy insights into the rational scenario and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their headquarter, competitors, product/service type, application and specification, pricing, and gross margin.